Active, not recruitingPhase 2NCT03456843

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov May 13, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Yale University
Principal Investigator: Isaac Kim, MD
Yale University
Intervention: Antiandrogen Therapy(drug)
Enrollment: 190 enrolled
Eligibility: 18 years · MALE
Timeline: 2018 – 2027

Study locations (16)

City of Hope, Duarte, California, United States
University of California, Irvine, Irvine, California, United States
University of Southern California, Los Angeles, California, United States
Yale University, New Haven, Connecticut, United States
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Swedish Medical Services, Seattle, Washington, United States
Epworth Healthcare, East Melbourne, Australia, Australia
Chinese University of Hong Kong, Hong Kong, China
Kindai University, Ōsaka-sayama, Osaka, Japan
Akita University, Akita, Japan
Juntendo University, Tokyo, Japan
National Cancer Center, Goyang-si, South Korea
Seoul National University Bundang Hospital, Gyeonggi-do, South Korea
Samsung Medical Center, Seoul, South Korea
+1 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03456843 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials